Pediatrix Medical Group (NYSE: MD - Get Free Report) and Amarantus Bioscience (OTCMKTS:AMBS - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, profitability, risk, earnings, analyst recommendations and valuation. Earnings and Valuation This table compares Pediatrix

Pediatrix Medical Group (NYSE: MD - Get Free Report) and Getinge (OTCMKTS:GNGBY - Get Free Report) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, dividends, valuation, earnings and profitability. Profitability This table compares Pediatrix Medical Group and

Investors target stocks that have been on a bullish run. Stocks like KSS, HRTG, MD and NEM are seeing price strength, and the momentum is likely to continue.

Pediatrix Medical Group (MD) reported earnings 30 days ago. What's next for the stock?

Brandes Investment Partners LP lowered its holdings in shares of Pediatrix Medical Group, Inc. (NYSE: MD) by 18.1% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 565,212 shares of the company's stock after selling 124,946 shares during the period.

Geode Capital Management LLC reduced its stake in Pediatrix Medical Group, Inc. (NYSE: MD) by 0.8% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,998,830 shares of the company's stock after selling 15,298 shares during the period. Geode Capital Management LLC

Pediatrix Medical Group (MD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

MD, LZB and CIB made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on Nov. 24, 2025.

AS, ISRG, MD, SHIP and CIB have been added to the Zacks Rank #1 (Strong Buy) List on Nov. 24, 2025.

JBSS, CIB and MD made it to the Zacks Rank #1 (Strong Buy) value stocks list on Nov. 24, 2025.